Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for IONS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -496.43M
March 31, 2026 -910.63M
December 31, 2025 -268.58M
September 30, 2025 -247.01M
June 30, 2025 -230.57M
March 31, 2025 -501.78M
December 31, 2024 -500.95M
September 30, 2024 -351.94M
June 30, 2024 -345.98M
March 31, 2024 -323.46M
December 31, 2023 -307.51M
September 30, 2023 -540.57M
June 30, 2023 -455.98M
March 31, 2023 -376.71M
December 31, 2022 -274.37M
September 30, 2022 129.51M
June 30, 2022 98.37M
March 31, 2022 53.81M
December 31, 2021 30.80M
September 30, 2021 -74.91M
June 30, 2021 -29.61M
March 31, 2021 -11.18M
December 31, 2020 35.89M
September 30, 2020 215.85M
June 30, 2020 213.32M
Date Value
March 31, 2020 230.42M
December 31, 2019 345.72M
September 30, 2019 183.28M
June 30, 2019 170.08M
March 31, 2019 697.43M
December 31, 2018 602.89M
September 30, 2018 507.80M
June 30, 2018 562.52M
March 31, 2018 64.65M
December 31, 2017 174.15M
September 30, 2017 127.79M
June 30, 2017 122.48M
March 31, 2017 86.33M
December 31, 2016 -112.10M
September 30, 2016 -123.62M
June 30, 2016 -110.81M
March 31, 2016 -11.82M
December 31, 2015 21.12M
September 30, 2015 129.28M
June 30, 2015 95.01M
March 31, 2015 -4.213M
December 31, 2014 6.285M
September 30, 2014 -78.89M
June 30, 2014 -15.01M
March 31, 2014 41.74M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 885.89M
Biogen, Inc. 2.879B
BridgeBio Pharma, Inc. -434.37M
Vertex Pharmaceuticals, Inc. 4.293B
Arrowhead Pharmaceuticals, Inc. -59.06M